Brought to you by 
Intarcia gets $215mm in first close of Series EE financing round; adds $206mm in second close
03 Jan 2017
Executive Summary
Metabolic disease-focused Intarcia Therapeutics Inc. received $215mm in late-stage equity financing from institutional investors, family offices, and China's Lucion Venture Capital Group. The company expects to receive additional funding in Q4. Intarcia will use the proceeds to help with the regulatory approval and launch (expected late next year) of its ITCA650 (exenatide) for Type II diabetes. Morgan Stanley was the placement agent.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Medical Devices
- Implantable Devices
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Intarcia gets $215mm in first close of Series EE financing round; adds $206mm in second close
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice